How to Verify a Compounding Pharmacy

The five checks

Ask which pharmacy fills the prescription, by name. Search your state board's licensee register for it. Check the FDA registered outsourcing facility list if a 503B is named. Search FDA warning letters by company name. And ask whether batches are tested for sterility and potency.

All five are free, none requires clinical training, and all can be done before you hand over a medical history.

The three answers you will get

A name and a licence number is the good one. A category — 'a licensed 503A partner' — is incomplete but honest about what it is not telling you. A deflection about proprietary partnerships is the answer, and the answer is no.

Why this matters more here than for approved medicines

An approved product has been reviewed before marketing and made under a federal quality system. A compounded preparation has not; its assurance comes from the pharmacy, the state board and, at good operations, batch testing. That is a legitimate framework that puts more of the verification burden on you.

What this changes about the programme you pick

Very little on its own, which is the honest answer. Almost every decision in this market comes back to three questions: what will I pay at the dose I actually hold, who compounds it, and what happens if I stop. A page that does not move one of those three is decoration.

Where this one moves the needle is on the first. Run the figure at your expected maintenance dose rather than the advertised one, and the ranking you were shown elsewhere frequently inverts.

How to check the numbers above

Every figure carries a capture date and an evidence status. Prices marked verified were read on the provider's own page; the rest came from named third-party sources and are treated as indicative. Open the dataset, re-sort it, and see whether our published order reproduces.

If it does not, that is a bug or a lie and you can find it without our help. If our figure and a provider's own page disagree, ours is wrong and we want to know.

What is deliberately absent

Shipping reliability, response times, and whether the clinical oversight is any good. We hold no measurements of those we would defend, so they appear nowhere in our tables rather than being estimated into a score.

That is why there is no rating out of ten on this site. A single number would compress price, disclosure, service and clinical depth into one figure and hide the weighting. We publish the inputs instead so you can weight them yourself.

What the spread tells you

All-in cost at a 10 mg maintenance dose runs from $215 to $548 across the 17 programmes we price. That is the identical molecule from the same category of licensed pharmacy, so the difference is overhead, clinical wrap, sourcing and margin rather than the medicine.

A 2.5-times spread on an identical product is unusual outside markets where buyers cannot easily compare, which is exactly the condition this site exists to remove.

Price the dose you will actually hold

The single most valuable correction anyone reading this can make. Advertised figures describe the 2.5 mg starter dose, which occupies about four weeks of a twelve-month course. Ten of your first twelve months are spent at or near a maintenance dose.

On a dose-scaled programme those are different numbers. On a flat programme they are not, which is the entire argument for flat pricing and the reason it is worth paying a little more at initiation for it.

The verification step most people skip

Ask which pharmacy fills the prescription, by name, then search your state board's licensee register for it. It is free, takes about two minutes, and fewer than a fifth of priced programmes publish enough to let you do it.

A programme that names a pharmacy has given you something checkable. One that describes a category has told you what it is not telling you. One that deflects has answered the question.

Two questions that settle most of it

What will I pay in total in month six at 10 mg, including every fee? A flat, all-inclusive programme answers in one sentence. A split-pricing programme needs three, because the answer depends on whether your insurance pays for the medication. A programme that cannot answer at all has told you something.

Which pharmacy fills it, and is the prescriber licensed in my state? Both are checkable against public registers, both are free, and neither requires you to trust us or the programme.

What a good answer looks like in writing

A figure with a dose attached. A named pharmacy with a state licence number. A cancellation notice period. A statement that the preparation is compounded and not FDA-approved. And a renewal rate that matches the rate you were quoted.

Getting those five in an email before you pay costs nothing and resolves almost every dispute that appears in complaint records for this category. The programmes that answer promptly are, in our reading of the public record, rarely the ones patients later write about.

How current this is

Prices captured 2026-08-05. Every figure on this page carries that date and an evidence status saying whether we read it at the provider or took it from a third party. Pricing in this market has moved repeatedly during 2026, and several large programmes stopped selling compounded tirzepatide entirely.

Treat any comparison older than a month — including this one — as needing a re-check before you act on it. The dataset is republished on every build.

The three numbers worth carrying away

The cheapest verified all-in cost at a maintenance dose: $215 a month, $2,580 for a first year. The share of priced programmes charging a mandatory recurring fee on top of medication: 6 of 17. And the share naming a dispensing pharmacy before purchase: fewer than a fifth.

Those three settle more purchasing decisions than any narrative comparison, and all three are reproducible from the file.

What most published comparisons get wrong about this

They compare advertised figures, which are not comparable to one another. One programme quotes medication only, another bundles a mandatory membership, a third quotes a promotional first month that reverts, a fourth reprices you as the dose climbs, and a fifth charges a programme fee with medication billed separately.

Ranking those five on their headline numbers produces an order that is wrong in a predictable direction: the programmes with the most aggressive fee structures look cheapest.